MP22-13 HOW SAFE IS EXTENDED PHARMACOLOGICAL VENOUS THROMBOEMBOLISM PROPHYLAXIS (EPVTEP) FOR PATIENT UNDERGOING RADICAL CYSTECTOMY?

Autor:	Daniel Parker, Zachary Piotrowski, Robert G. Uzzo, David Y.T. Chen, Jeffrey J. Tomaszewski, Philip Abbosh, Marc C. Smaldone, Timothy Ito, Kevan Iffrig, Reza Mehrazin, Paul Bloch, Brian L. Egleston, Richard E. Greenberg, Rosalia Viterbo, Alexander Kutikov
Rok vydání:	2014
Předmět:	medicine.medical_specialty Bladder cancer medicine.diagnostic_test business.industry Urology medicine.medical_treatment Urine Cancer detection Cystoscopy medicine.disease Surgery Cystectomy Active disease medicine business Venous thromboembolism Urine cytology
Zdroj:	Journal of Urology. 191
ISSN:	1527-3792 0022-5347
DOI:	10.1016/j.juro.2014.02.861
Popis:	INTRODUCTION AND OBJECTIVES: Bladder cancer is routinely detected and monitored by cystoscopy and urine cytology. Urine cytology assay is limited because of its low sensitivity (especially for low-grade tumors). Nevertheless, it is highly specific and can occasionally detect tumors that are missed by cystoscopy. Several alternative molecular assays were previously developed with the aim of complementing and/or replacing urine cytology, however, they also failed to reach high sensitivity and/or specificity and therefore were not widely used. In this study we describe a new approach for cancer detection in urine samples based upon epigenetic changes. This assay produces a DNA methylation "fingerprint" for urine. METHODS: The assay ( "Bladder EpiCheck") is based on methylation-sensitive restriction of DNA in urine followed by quantitative amplification of 15 genomic loci that are hyper-methylated in bladder cancer. The resulting “fingerprint” is automatically analyzed by dedicated software that outputs the diagnosis and provides a quantitative EpiScore. The assay was developed on 109 urine samples from bladder cancer patients e 69 with and 40 without currently active disease. RESULTS: The assay was tested on a “fresh batch” of 67 samples and detected 94% (including all high grade) tumors at a specificity of 84%. Using an alternative cut-off value the assay detected 81% of tumors at a specificity of 96%. CONCLUSIONS: “Bladder EpiCheck” is a powerful new non-invasive tool for bladder cancer detection and monitoring. Further studies are required to approve its high sensitivity and specificity.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3284bba1954f0879248087d6dc96f453 https://doi.org/10.1016/j.juro.2014.02.861 Zobrazit plný text záznamu